Vise Technologies Inc. purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,659 shares of the biotechnology company’s stock, valued at approximately $899,000.
A number of other hedge funds have also recently modified their holdings of UTHR. E Fund Management Co. Ltd. purchased a new position in United Therapeutics during the second quarter worth about $413,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $459,000. Johnson Financial Group Inc. purchased a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $289,000. Tocqueville Asset Management L.P. acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $38,946,000. Finally, West Family Investments Inc. acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $287,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.
United Therapeutics Stock Performance
Shares of UTHR stock opened at $513.12 on Monday. The firm has a market cap of $22.01 billion, a P/E ratio of 18.36, a P/E/G ratio of 1.74 and a beta of 0.59. The firm’s 50 day moving average price is $533.08 and its 200-day moving average price is $537.80. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35.
Analysts Set New Price Targets
UTHR has been the topic of a number of recent analyst reports. Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $646.00.
Check Out Our Latest Analysis on UTHR
Insider Buying and Selling at United Therapeutics
In related news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $547.62, for a total value of $5,202,390.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,185,729.06. The trade was a 19.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,311,581.28. The trade was a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 442,575 shares of company stock valued at $239,326,330. Company insiders own 8.60% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
- Five stocks we like better than United Therapeutics
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
